Company Contact: Hua Da Trading Inc dba Wefun Inc
Name: Daniel Zeng
Phone Number: 929-509-7343

FOR IMMEDIATE RELEASE – 08/25/2023 – Brooklyn, New York, Hua Da Trading Inc dba Wefun Inc is voluntarily recalling 300 Boxes of WEFUN Capsules to the consumer level. FDA analysis has found the product to be tainted with sildenafil. Sildenafil is an ingredient known as a Phosphodiesterase Inhibitor (PDE-5) inhibitor found in FDA-approved products for the treatment of male erectile dysfunction. The presence of sildenafil in this product renders it an unapproved drug for which the safety and efficacy has not been established and, therefore, subject to recall.

Risk Statement: Consumption of products with undeclared sildenafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Among the adult male population, who are most likely to use this product, adult males who use nitrates for cardiac conditions are most at risk. Hua Da Trading Inc dba Wefun Inc has not received any reports of adverse events related to this recall.

The tainted marketed as a dietary supplement and is packaged in a blue cardboard box (10 capsules).  The affected WEFUN Capsule lot includes the following .  The WEFUN Capsules was distributed Nationwide in the USA via internet sales via and

Hua Da Trading Inc dba Wefun Inc is notifying its distributors and customers by email and is arranging for return of all recalled WEFUN capsules.  Consumers/distributors/retailers that have WEFUN capsules which is being recalled should
Consumers with questions regarding this recall can contact Hua Da Trading Inc dba Wefun Inc 7 Days a week from 9am-7pm Eastern Time, or e-mail address   Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.